ArticleJournal of virology2013
Protection against lethal influenza with a viral mimic.
Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 69 citations in OpenAlex.
- Host PI3K inhibition via anti-cancer drug alpelisib influences Influenza A non-infectious particles and deletion-containing viral genomes.Cell communication and signaling : CCS · 2025Article
- Structure and function of a cross-neutralizing influenza neuraminidase antibody that accommodates recent N2 NA Asn245 glycosylation.Communications biology · 2025Article
- Review
- In vivo secondary structural analysis of Influenza A virus genomic RNA.Cellular and molecular life sciences : CMLS · 2023Article
- Development of a Mouse Model to Explore CD4 T Cell Specificity, Phenotype, and Recruitment to the Lung after Influenza B Infection.Pathogens (Basel, Switzerland) · 2022Article
- Generation and Characterization of Single-Cycle Infectious Canine Influenza A Virus (sciCIV) and Its Use as Vaccine Platform.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection.Journal of virology · 2021Article
- Increasing the Safety Profile of the Master Donor Live Attenuated Influenza Vaccine.Pathogens (Basel, Switzerland) · 2020Article
- In vivo rescue of recombinant Zika virus from an infectious cDNA clone and its implications in vaccine development.Scientific reports · 2020Article
- Ataxia-telangiectasia mutated is required for the development of protective immune memory after influenza A virus infection.American journal of physiology. Lung cellular and molecular physiology · 2019Article
- Article
- Article
- Secondary structure of the segment 5 genomic RNA of influenza A virus and its application for designing antisense oligonucleotides.Scientific reports · 2019Article
- Review
- Functional Evolution of the 2009 Pandemic H1N1 Influenza Virus NS1 and PA in Humans.Journal of virology · 2018Article
- Development and application of bioluminescence imaging for the influenza A virus.Journal of thoracic disease · 2018Review
- A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody.Scientific reports · 2018Article
- Article
- Review
- Influenza virus segment 5 (+)RNA - secondary structure and new targets for antiviral strategies.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Despite countermeasures against influenza virus that prevent (vaccines) and treat (antivirals) infection, this upper respiratory tract human pathogen remains a global health burden, causing both seasonal epidemics and occasional pandemics. More potent and safe new vaccine technologies would contribute significantly to the battle against influenza and other respiratory infections. Using plasmid-based reverse genetics techniques, we have developed a single-cycle infectious influenza virus (sciIV) with immunoprotective potential. In our sciIV approach, the fourth viral segment, which codes for the receptor-binding and fusion protein hemagglutinin (HA), has been removed. Thus, upon infection of normal cells, although no infectious progeny are produced, the expression of other viral proteins occurs and is immunogenic. Consequently, sciIV is protective against influenza homologous and heterologous viral challenges in a mouse model. Vaccination with sciIV protects in a dose- and replication-dependent manner, which is attributed to both humoral responses and T cells. Safety, immunogenicity, and protection conferred by sciIV vaccination were also demonstrated in ferrets, where this immunization additionally blocked direct and aerosol transmission events. All together, our studies suggest that sciIV may have potential as a broadly protective vaccine against influenza virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.